Reactive Hypoglycemia as a Transient Metabolic Phenotype of Stage 1 and 2 Type 1 Diabetes

May combine two claims.

Sutkowska et al. described a 31-year-old woman with recurrent postprandial or exertional reactive hypoglycemia and exaggerated insulin secretion during oral glucose tolerance test, initially considered to have hyperinsulinemic reactive hypoglycemia before positive anti-GAD and anti-insulin antibodies led to a diagnosis of pre-stage 3 autoimmune T1D during follow-up.

“Sutkowska et al. (2) described a 31-year-old woman with recurrent postprandial or exertional reactive hypoglycemia and exaggerated insulin secretion during oral glucose tolerance test.”

• Also stated in: § Reactive Hypoglycemia as a Transient Metabolic Phenotype of Stage 1 and 2 Type 1 Diabetes · plain

  “She was initially considered to have hyperinsulinemic reactive hypoglycemia before positive anti-GAD and anti-insulin antibodies led to a diagnosis of pre–stage 3 autoimmune T1D during follow-up.”

• cites [2] Sutkowska, 2021, Insulin autoimmune syndrome as part of pre-clinical LADA, Diabetes Metab Syndr Obes sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Stage 2 disease is usually recognized through dysglycemia resembling prediabetes, such as impaired glucose tolerance or rising HbA1c.

“Stage 2 disease is usually recognized through dysglycemia resembling prediabetes, such as impaired glucose tolerance or rising HbA1c (1).”

• cites [1] Phillip, 2024, Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes [published correction appears in Diabetes Care 2024;47:2033], Diabetes Care sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Patient 2 had a lean phenotype (BMI 20 kg/m2) without insulin resistance.

“She had a lean phenotype (BMI 20 kg/m2) without insulin resistance.”

May combine two claims.

In Patient 3, over time postprandial hyperglycemia progressively increased while symptomatic hypoglycemia became less frequent.

“Over time, postprandial hyperglycemia progressively increased while symptomatic hypoglycemia became less frequent.”

May combine two claims.

Patient 3 had two postprandial episodes (2.8 and 2.6 mmol/L) confirmed by capillary testing and a history of prior fainting episodes, including one severe hypoglycemic event documented in the emergency department (<3.0 mmol/L).

“Two postprandial episodes (2.8 and 2.6 mmol/L) were confirmed by capillary testing, and the history revealed prior fainting episodes, including one severe hypoglycemic event documented in the emergency department (<3.0 mmol/L).”

May combine two claims.

In Patient 3, at M+21 persistent hyperglycemia indicated progression to stage 3 T1D, with disappearance of hypoglycemia.

“At M+21, persistent hyperglycemia (orange) indicates progression to stage 3 type 1 diabetes, with disappearance of hypoglycemia.”

May combine two claims.

Patient 2 reported 4 years of postprandial hypoglycemic symptoms relieved by carbohydrate intake, with several episodes confirmed by capillary glucose <2.7 mmol/L.

“Patient 2, a 25-year-old woman with Hashimoto thyroiditis, reported 4 years of postprandial hypoglycemic symptoms relieved by carbohydrate intake, with several episodes confirmed by capillary glucose <2.7 mmol/L.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Patient 2 had strongly positive anti-GAD and weakly positive anti-IA2 antibodies.

“Autoimmune testing showed strongly positive anti-GAD and weakly positive anti-IA2 antibodies.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Patient 3 had obesity (BMI 35 kg/m2) and acanthosis nigricans.

“she had obesity (BMI 35 kg/m2) and acanthosis nigricans”

Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.

Recognizing this presentation may improve early identification of presymptomatic autoimmune diabetes, support appropriate monitoring, and help avoid missed opportunities for disease-modifying intervention.

“Recognizing this presentation may improve early identification of presymptomatic autoimmune diabetes, support appropriate monitoring, and help avoid missed opportunities for disease-modifying intervention.”

May combine two claims.

Patient 3 progressed to stage 3 autoimmune diabetes, with worsening dysglycemia leading to basal-bolus insulin therapy several months later despite metformin and semaglutide.

“Despite treatment with metformin and semaglutide, worsening dysglycemia led to basal-bolus insulin therapy several months later, confirming progression to stage 3 autoimmune diabetes.”

May combine two claims.

Patient 1 progressed to stage 3 disease approximately 3 years later, with insulin initiation after progressive HbA1c increase and persistent postprandial dysglycemia despite acarbose and sitagliptin.

“Despite treatment with acarbose and sitagliptin, HbA1c progressively increased and CGM showed persistent postprandial dysglycemia, leading to insulin initiation ∼3 years later, consistent with progression to stage 3 disease.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Patient 3's obesity and acanthosis nigricans suggested insulin resistance.

“she had obesity (BMI 35 kg/m2) and acanthosis nigricans, suggesting insulin resistance.”

May combine two claims.

Presymptomatic stage 1 and 2 T1D-associated hypoglycemia has been more frequently reported in children, where predominantly postprandial and transient episodes appeared associated with preserved endogenous insulin secretion before progression to overt diabetes.

“In contrast, presymptomatic stage 1 and 2 T1D-associated hypoglycemia has been more frequently reported in children, where predominantly postprandial and transient episodes appeared associated with preserved endogenous insulin secretion before progression to overt diabetes (3,4).”

• cites [3] Rafeullah, 2012, Fasting hypoglycaemia and postprandial hyperglycaemia as a prodrome of type 1 diabetes mellitus, Horm Res Paediatr sourceNot checked — no full text of the source
• cites [4] Yamaguchi, 2019, Hypoglycemia in type 1A diabetes can develop before insulin therapy: a retrospective cohort study, Diabetes Res Clin Pract sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

Recurrent unexplained reactive hypoglycemia, particularly in individuals without a clear pre-type 2 diabetes phenotype, with autoimmune features, or with a family history of T1D, may represent a clinical clue warranting islet autoantibody testing.

“Beyond monitored cohorts, recurrent unexplained reactive hypoglycemia, particularly in individuals without a clear pre–type 2 diabetes phenotype, with autoimmune features, or with a family history of T1D may represent a clinical clue warranting islet autoantibody testing.”